Ferry B L, Welsh K I, Dunn M J, Law D, Proctor J, Chapel H, Yacoub M H, Rose M L
Department of Immunology, Churchill Hospital, Oxford, UK.
Transpl Immunol. 1997 Mar;5(1):17-24. doi: 10.1016/s0966-3274(97)80021-4.
The aetiologies of accelerated or transplant-associated coronary artery disease (TxCAD) following cardiac transplantation and chronic rejection following renal transplantation remain ill-defined. Previous studies have used Western blotting to demonstrate an association between the formation of anti-endothelial (anti-EC) antibodies and TxCAD after heart transplantation. However, Western blotting favours detection of cytosolic proteins. The objectives of this study were to determine whether flow cytometry, a method which detects antigens on the cell surface, could be used to detect anti-EC antibodies and also whether the observations would extend to renal transplant patients with chronic rejection. Flow cytometry was used to look for antibodies reactive with the surface antigens of macrovascular and microvascular endothelial cell lines in sera from 44 cardiac and 35 renal transplant recipients before and after transplantation. In addition, sera from normals (n = 20), patients with nontransplant CAD (n = 50) and patients with unrelated diseases (n = 40) were investigated. Of 23 cardiac recipients who had developed TxCAD at one or two years post-transplant, 61% had IgM and 13% had IgG anti-EC antibodies post-transplantation. In contrast, in 21 cardiac recipients who had not developed TxCAD 14% had IgM and 14% IgG anti-EC antibodies. There was little evidence for the presence of anti-EC antibodies in cardiac recipients before transplantation. Of 26 renal transplant recipients whose transplants failed due to chronic rejection, 42% had IgG and 19% IgM anti-EC antibodies post-transplantation. Of nine renal recipients whose grafts were either functioning normally or who had acutely rejected, none had IgG or IgM anti-EC antibodies either pre- or post-transplantation. The anti-EC antibodies were not found in normals and were rare (less than 4%) in the other disease groups; they do not appear to be autoantibodies. In conclusion, these results suggest the FACS assay could be an informative and rapid test to provide more information on chronic rejection following cardiac and renal transplantation.
心脏移植后加速性或移植相关冠状动脉疾病(TxCAD)的病因以及肾移植后的慢性排斥反应仍未明确界定。以往研究使用蛋白质印迹法证明心脏移植后抗内皮(抗EC)抗体的形成与TxCAD之间存在关联。然而,蛋白质印迹法更有利于检测胞质蛋白。本研究的目的是确定流式细胞术(一种检测细胞表面抗原的方法)是否可用于检测抗EC抗体,以及这些观察结果是否也适用于患有慢性排斥反应的肾移植患者。流式细胞术用于检测44例心脏移植受者和35例肾移植受者移植前后血清中与大血管和微血管内皮细胞系表面抗原反应的抗体。此外,还对20名正常人、50名非移植性CAD患者和40名患有无关疾病的患者的血清进行了研究。在23名移植后1年或2年发生TxCAD的心脏移植受者中,61%在移植后有IgM抗EC抗体,13%有IgG抗EC抗体。相比之下,在21名未发生TxCAD的心脏移植受者中,14%有IgM抗EC抗体,14%有IgG抗EC抗体。几乎没有证据表明心脏移植受者在移植前存在抗EC抗体。在26例因慢性排斥反应导致移植失败的肾移植受者中,42%在移植后有IgG抗EC抗体,19%有IgM抗EC抗体。在9名移植功能正常或发生急性排斥反应的肾移植受者中,移植前或移植后均无IgG或IgM抗EC抗体。正常人中未发现抗EC抗体,其他疾病组中也很少见(低于4%);它们似乎不是自身抗体。总之,这些结果表明,流式细胞术检测可能是一种信息丰富且快速的检测方法,可为心脏和肾移植后的慢性排斥反应提供更多信息。